March 2022 in “Oncology Times” In this study, tebentafusp-tebn improved overall survival in patients with metastatic uveal melanoma compared to standard therapies, despite higher rates of significant adverse events.
108 citations
,
February 2013 in “JAMA” This review discusses the therapeutic options for transgender individuals, including hormonal and surgical treatments, and reports no new clinical results; the authors highlight the need for more research on long-term effects.
29 citations
,
January 2021 in “Translational Psychiatry” This study found that certain gene sets, including those involved in ligand-gated ion channel signaling and cell adhesion, are associated with Tourette syndrome, suggesting a potential neurobiological basis for the disorder.
6 citations
,
November 2010 in “Histochemistry and cell biology” This study found that transthyretin and megalin expression in human scalp hair follicles varies significantly with the hair growth cycle, peaking during anagen and diminishing in catagen and telogen phases.
39 citations
,
January 2019 in “Cells” This review discusses the molecular mechanisms of Hutchinson-Gilford progeria syndrome and evaluates current research trends, available mouse models, and prospects for developing therapies, but reports no new clinical findings.
158 citations
,
January 2003 in “Journal of Forensic Sciences” This study demonstrates that a single exposure to GHB during a sexual assault can be detected by analyzing hair segments collected about one month after the incident.
126 citations
,
February 2017 in “JAMA Surgery” This article outlines best practices from the World Professional Association for Transgender Health's standards to guide health care professionals in providing comprehensive care for transgender individuals, addressing mental health, endocrinology, and surgery.
14 citations
,
July 2011 in “Experimental Dermatology” In this study, topical EGCG significantly reduced testosterone-induced hair loss and follicular apoptosis in mice, without altering testosterone or dihydrotestosterone concentrations.
31 citations
,
November 2003 in “Journal of Occupational Health” This study found that the reproductive function of female hairdressers may be negatively affected by long-term exposure to permanent-waving solutions containing thioglycolic acid, raising concerns about its potential carcinogenic effects.
1 citations
,
November 2023 in “American journal of clinical pathology” This case report highlights a rare occurrence of poorly differentiated endometrial carcinoma in a transgender man undergoing long-term testosterone therapy, underscoring the necessity of continued gynecologic care and further research into the effects of testosterone on endometrial health in this population.
October 2022 in “Hair Transplantation” This article discusses the temporary scalp trichopigmentation procedure, detailing its unique approach compared to traditional scalp micropigmentation, and reports no new clinical findings.
May 2026 in “Meditsinskiy sovet = Medical Council” This review outlines the benefits of menopausal hormone therapy for improving skin properties in peri- and postmenopausal women, emphasizing that interdisciplinary management enhances quality of life but noting the aesthetic improvements are secondary outcomes.
September 2022 in “Medical Mycology” This study found that three protocols for generating Titan cells in vitro from Candida neoformans vary in their kinetics and transcriptomic profiles, pointing to differences which could impact further research.
37 citations
,
January 2010 in “Human Molecular Genetics” In this study using mice with specific gene knockouts, both farnesyltransferase and geranylgeranyltransferase-I were found to be essential for the proliferation and survival of skin keratinocytes.
November 2022 in “Journal of Investigative Dermatology” This study found that autologous γdTregs displayed significant protective effects on alopecia areata-affected human scalp hair follicles in both ex vivo and in vivo settings, suggesting potential for future cell-based therapy.
July 2025 in “The Egyptian Journal of Hospital Medicine” This study found that serum GPER-1 levels may serve as a biomarker for differentiating androgenetic alopecia from telogen effluvium and healthy controls, although its ability to distinguish between AGA and TE is limited.
9 citations
,
October 2025 in “MedComm” This review discusses the development and clinical progression of PROTAC technology for targeted protein degradation, highlighting its potential to address previously "undruggable" targets but reports no new clinical results.
January 2005 in “Translational and Clinical Pharmacology” HDMHG0401-10 improves hair loss in men with androgenetic alopecia and has no major side effects.
May 2025 in “Anadolu Kliniği Tıp Bilimleri Dergisi” This study found that in male patients with androgenic alopecia, individuals with certain glutathione S-transferase gene polymorphisms exhibited higher oxidative stress and lower antioxidant capacity, although differences were not statistically significant, and oxidative stress appeared to increase with the progression of alopecia stages.
5 citations
,
September 2021 in “Southern African Journal of Hiv Medicine” The guideline provides healthcare professionals in South Africa with instructions for comprehensive, multidisciplinary gender-affirming care, including HIV prevention and treatment for transgender and gender diverse individuals.
March 2026 in “Drug Testing and Analysis” This study observed that the degradation product PTeCA significantly increased in hair treated with oxidative cosmetics, suggesting it could be a reliable marker for detecting such treatments, with a proposed PTCA cut-off value using PTeCA as the gold standard.
July 2023 in “Journal of the ASEAN Federation of Endocrine Societies” In this study of a postmenopausal woman with hyperandrogenism, GnRH agonist treatment significantly reduced testosterone levels, suggesting the androgen excess was ovarian in origin and indicating the potential of using GnRH agonists as a conservative treatment option when surgery is not feasible.
November 2025 in “Cosmetics” This review discusses the clinical efficacy, safety, and mechanisms of Autologous Micrografting Technology for androgenetic alopecia, reporting significant short-term improvements in hair density and thickness.
9 citations
,
January 1997 in “Endocrine Journal” This study found a significant association between patients' sex of rearing and external genitalia in those with gonadal dysgenesis, while noting lower testosterone levels compared to controls.
March 2025 in “Journal of Cosmetic Dermatology” This study explored the effects of TTFE on male androgenic alopecia, finding that topical application increased hair density, follicular diameter, and scalp hydration while reducing water loss and sebum production in a 12-week trial.
March 2026 in “Journal of Investigative Dermatology” This study found that GPT-4o demonstrated high concordance with in-person and image-based provider assessments in generating SALT scores for alopecia areata, suggesting its potential as an adjunct tool in clinical practice for automating these assessments.
March 2024 in “Journal of Cosmetic Dermatology” This study found that pretreating concentrated growth factor with a 640 nm laser increased CD34+ stem cell activation and improved hair growth outcomes in androgenetic alopecia patients compared to non-pretreated CGF.
7 citations
,
August 2011 in “Giornale italiano di dermatologia e venereologia : organo ufficiale, Società italiana di dermatologia e sifilografia” This study found that the modified wash test demonstrated high reliability in diagnosing and assessing the severity of androgenetic alopecia and telogen effluvium.
42 citations
,
January 2015 in “Polskie Archiwum Medycyny Wewnętrznej” This study found that certain gene polymorphisms, specifically MTHFR 677CC and GGH 401TT and CT genotypes, were associated with fewer adverse effects from methotrexate in rheumatoid arthritis patients.
May 2025 in “Oxford Academix (Oxford)” This study reported that there are no standardized guidelines for managing testosterone-induced acne vulgaris and androgenic alopecia in transmasculine or non-binary individuals undergoing gender-affirming hormone therapy, highlighting gaps in dermatology trainees’ preparedness to care for this population.